SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

Press Release: Hillrom's Fiscal First Quarter -2-

· 02/05/2021 06:59
Hill-Rom Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) (In millions, except per share data) Three Months Ended December 31 2020 2019 Net Revenue Product sales and service $ 652.5 $614.3 Rental revenue 88.6 70.7 Total net revenue 741.1 685.0 Cost of Net Revenue Cost of goods sold 324.2 306.3 Rental expenses 37.7 37.0 Total cost of net revenue (excludes acquisition-related intangible asset amortization) 361.9 343.3 Research and development expenses 34.8 31.5 Selling and administrative expenses 209.0 196.8 Acquisition-related intangible asset amortization 25.9 26.7 Special charges 27.1 7.8 Operating Profit 82.4 78.9 Interest expense (17.8) (19.4) Loss on extinguishment of debt -- (15.6) Investment income (expense) and other, net 7.0 (1.3) Income Before Income Taxes 71.6 42.6 Income tax expense 12.8 2.8 Net Income $ 58.8 $39.8 Net Income per Basic Common Share $ 0.88 $0.60 Net Income per Diluted Common Share $ 0.88 $0.59 Average Basic Common Shares Outstanding (in thousands) 66,497 66,792 Average Diluted Common Shares Outstanding (in thousands) 66,925 67,329 Hill-Rom Holdings, Inc. and Subsidiaries Revenue Constant Currency (Unaudited) (In millions) U.S. OUS Three Months Ended December Change As Constant Change As Change As Constant 31 Reported Currency Reported Reported Currency 2020 2019 Net Revenue: Product sales and service $652.5 $614.3 6.2 % 4.4 % (2.8) % 25.7 % 19.9 % Rental revenue 88.6 70.7 25.3 % 24.3 % 28.1 % 6.5 % (1.1) % Total net revenue $741.1 $685.0 8.2 % 6.5 % 1.2 % 24.8 % 18.9 % Net Revenue: Patient Support Systems $377.4 $344.2 9.6 % 8.0 % 0.9 % 39.8 % 32.7 % Front Line Care 269.9 254.6 6.0 % 5.0 % 3.6 % 11.6 % 8.2 % Surgical Solutions 93.8 86.2 8.8 % 4.4 % (7.8) % 21.4 % 13.6 % Total net revenue $741.1 $685.0 8.2 % 6.5 % 1.2 % 24.8 % 18.9 % OUS - Outside of the United States Hill-Rom Holdings, Inc. and Subsidiaries Reconciliation: Earnings Per Share (Unaudited) (In millions, except per share data) Three Months Ended December 31, 2020 Three Months Ended December 31, 2019 Income Income Before Income Before Income Operating Income Tax Diluted Operating Income Tax Margin Taxes Expense EPS Margin Taxes Expense Diluted EPS GAAP Basis 11.1% $71.6 $ 12.8 $ 0.88 11.5 % $ 42.6 $ 2.8 $ 0.59 Adjustments: Acquisition and integration costs and related fair value adjustments -- % (0.1) -- -- (1.0)% (6.6) 0.3 (0.10) Acquisition-related intangible asset amortization 3.5 % 25.9 6.3 0.29 4.0 % 26.7 6.4 0.30 Regulatory compliance costs 0.5 % 4.1 1.0 0.05 0.6 % 3.9 0.6 0.05 Special charges 3.7 % 27.1 6.2 0.31 1.1 % 7.8 1.2 0.10 Debt refinancing costs -- % -- -- -- -- % 16.1 3.7 0.18 Loss on business combinations -- % -- -- -- -- % 0.5 0.1 0.01 COVID-19 related costs and benefits, net -- % (0.1) -- -- -- % -- -- --

The company also routinely provides earnings per diluted share guidance on an adjusted basis. This excludes the impact of intangible asset amortization associated with prior business acquisitions, which we expect to be $1.18 - $1.23 per diluted share for the fiscal year 2021. Management also does not include adjusted items such as strategic developments, acquisition and integration costs, special charges, and other special items or unusual items in our guidance because such items are evaluated on an ongoing basis, can be highly variable and cannot be reasonably predicted. As such, prospective quantification of these items is not feasible, and a full reconciliation of non-GAAP earnings per diluted share guidance to GAAP earnings per diluted share has not been provided. However, as a result of acquisitions, our ongoing portfolio and business optimization initiatives, and any change to the transitional impacts from U.S. tax reform legislation, we do expect adjusted items we have not predicted to potentially be significant to our GAAP measures including gross margin, operating margin, income tax expense and earnings per diluted share.

The company also presents certain results on a constant currency basis, which compares results between periods as if foreign currency exchange rates had remained consistent period-over-period. Management monitors sales performance on an adjusted basis that eliminates the positive or negative effects that result from translating international sales into U.S. dollars. Management calculates constant currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period. Management believes that evaluating growth in net revenue on a constant currency basis provides an additional and meaningful assessment to both management and investors.

Conference Call Webcast and Dial-in Information

The company will host a conference call and webcast today beginning at 7:30 a.m. (CT) / 8:30 a.m. (ET).

Conference Call Audio Only Dial-in Information: To participate in the conference call dial (844) 654-5620 (domestic) or (647) 253-8654 (international). Please dial into the call at least 10 minutes prior to the start to allow time to connect. The confirmation code is 1588314.

Webcast: A simultaneous webcast of the call will be accessible via the company's website at www.hillrom.com. A supplementary presentation will be posted to the Hillrom website prior to the webcast.

A recording of the webcast/call audio will be available for telephone replay for a period of 7 days following the earnings call. To access the replay, dial (800) 585-8367 (domestic) or (416) 621-4642 (international). For the replay, callers will need to use confirmation code 1588314. If you are unable to listen to the live webcast or the telephone replay, the webcast will be archived at www.hillrom.com.

About Hillrom

Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care(TM). Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical effici0ency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.

Disclosure Regarding Forward-Looking Statements

Certain statements in this release relating to Hillrom's future plans, objectives, beliefs, expectations, representations and projections, including but not limited to those made with respect to the BardyDx transaction, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. It is important to note that forward-looking statements involve significant risks and uncertainties and are not guarantees of future performance, and Hillrom's actual results could differ materially from those set forth in any forward-looking statements. For a more in-depth discussion of factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in Hillrom's previously filed most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Hillrom assumes no obligation to update or revise any forward-looking statements, unless required by law.

(1) CDC Vision Health Initiative (VHI), Common Eye Disorders. www.cdc.gov/visionhealth/basics/ced/index.html.

(2) National Eye Institute. Diabetic Retinopathy. https://www.nei.nih.gov/sites/default/files/2019-06/diabetes-prevent-vision-loss.pdf. Accessed Sep-2, 2020.

(3) Medicare Program; CY 2021 Payment Policies under the Physician Fee Schedule Proposed Rule [CMS-1734-P], 08/17/2020.

(4) Vincent JL, Einav S, Pearse R, et al. Improving detection of patient deterioration in the general hospital ward environment. Eur J Anaesthesiol. 2018;35(5):325-333.

(MORE TO FOLLOW) Dow Jones Newswires

February 05, 2021 06:59 ET (11:59 GMT)